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Abstract 
The growth of the biopharmaceutical industry has created a demand for new technologies for 
the purification of genetically engineered proteins. The efficiency of large-scale, high-
gradient magnetic fishing could be improved if magnetic particles offering higher binding 
capacity and magnetization were available. This article describes several strategies for 
synthesizing SPMs that are composed of a M13 bacteriophage layer assembled on a 
superparamagnetic core. Chemically cross-linking the pVIII proteins to a carboxyl 
functionalized SPM produced highly responsive superparamagnetic particles with a side-on 
oriented, adherent virus monolayer. Also, the genetic manipulation of the pIII proteins with a 
His6 peptide sequence allowed reversible assembly of the bacteriophage on a nitrilotriacetic 
acid functionalized core in an end-on configuration. These phage-magnetic particles were 
successfully used to separate antibodies from high-protein concentration solutions in a single 
step with a > 90 % purity. The dense magnetic core of these particles makes them five times 
more responsive to magnetic fields than commercial materials composed of polymer-iron 
oxide composites and a monolayer of phage could produced a 1000 fold higher antibody 
binding capacity. These new bionanomaterials appear to be well-suited to large-scale high-
gradient magnetic fishing separation and promise to be cost effective as a result of the self-
assembling and self-replicating properties of genetically engineered M13 bacteriophage. 
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Formatted: Not Highlight
Formatted: Not Highlight
Submitted to  
 
 - 3 - 
1. Introduction 
A shift is taking place in the pharmaceutical industry whereby an increasing portion of the 
most successful new therapeutics is being derived from genetically engineered antibodies [1]. 
The efficient, large-scale production of high-purity recombinant proteins has thus become an 
important technical goal of the biopharmaceutical industry. Downstream processing (DSP) 
remains a bottleneck in the production of recombinant human biotherapeutic proteins, 
accounting for up to 80% of the manufacturing costs in some cases. Much of this cost can be 
attributed to the expense of chromatographic matrices, with bioaffinity types featuring protein 
ligands being at least an order of magnitude more expensive than ion exchange matrices 
employing the same base matrix. In specific, protein A is the standard for antibody 
purification due to its high-affinity for a wide-range of antibody sub-types and genetically 
engineered ability to withstand strong chemical conditions used to sterilize the affinity 
separation matrix [3]. 
Superparamagnetic microparticles (SPMs) have been widely used for single-molecule 
detection [4], cell sorting [5], nucleic acid together with protein purification [6], and in vivo 
magnetic resonance imaging [7]. The manipulation and separation of biomolecules and cells 
using SPMs offers a significantly faster rate of separation than traditional chromatography.  
High-gradient magnetic fishing (HGMF) is an integrated bioprocess product capture 
technology, employing specialised magnetic adsorbent particles in combination with high-
gradient magnetic separation equipment, to fish out and partially purify target bioproducts 
from complex unclarifed bioprocess liquors [6]. However, efficient large-scale HGMF requires 
that the SPMs have both a high magnetic moment and a high analyte binding capacity. These 
properties cannot be obtained with a simple spherical bead as the magnetic moment scales as 
[r3] while surface area/volume ratio scales as [r-1] [8]. This has led to the development of more 
complicated SPM structures where increased binding capacity is created through roughened 
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surfaces [9, 10]. 
Natural scaffolds have recently gained attention as a promising approach for building 
nanostructures due to their well-defined molecular shape, propensity to self-assemble, and 
ease of modification through genetic engineering [11-13]. In particular, the bacteriophage has 
been extensively used for molecular engineering [14, 15] and other applications [16, 17]. Phage-
based materials have been developed for biomedical applications including biosensing [18, 19], 
affinity purification [20-22], in vivo imaging [23-25], drug/gene delivery, and antibiotic 
therapies [26, 28]. The M13 bacteriophage is 6 nm in diameter and ~900 nm long virus [29] with 
a large surface area of 18,700 nm2 [30]. From a structural perspective, the virion is dominated 
by the 2,700 copies of the pVIII coat protein, representing 87 % of its total mass and 99 % of 
the total virus surface (Figure 1a). The N-termini of these proteins are flexible, hydrophilic 
domains, located on the outer surface of the phage and are able to support peptide inserts of 
up to 8 amino acids for display on every pVIII unit [31] (Figure 1b). The first eight amino acids 
of the pVIII subunit of wild-type M13 virus include two amino groups and three carboxyl 
groups that are exposed to solvent on the surface of the virion, thus they can be chemically 
modified without compromising the virion integrity and its infectivity [32] (Figure 1b and c). 
Five copies of each of the four minor coat proteins (pIII, pVI, pVII and pIX) close off the 
ends of the bacteriophage structure [33]. The N-terminal part of the pIII protein is the most 
widely used system to display foreign (poly)peptides, and random libraries on the phage 
surface (phage display technology, for review [34, 35]). The abundance of chemically 
addressable functionalities on the phage surface and the ability to manipulate the virus 
genome via molecular biology techniques have been used to create recombinant polymeric 
scaffolds [30, 36]. The phage structure is extraordinarily robust, being resistant to heat, organic 
solvents, acidic conditions, alkali conditions and even 6 M urea [29, 37]. Purified phage particle 
can also be stored at moderate temperature without jeopardizing its infectivity and/or binding 
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activity [21, 22, 31, 38]. 
This article describes strategies for modifying the M13 phage to allow it to be used as a multi-
functional material for HGMF affinity separation. Figure 1 shows a schematic of the M13 
phage coat proteins and genetic structure that have been used to modify the phage with 
functional groups for simultaneous assembly and affinity separation on SPMs. The pIII and 
pVIII phage coat proteins have been genetically and chemically modified, respectively, to 
allow the phage to assemble at high densities on SPMs. These high surface area 
bionanomaterials have proven to be highly functional for magnetically activated antibody and 
protein affinity separation. To the best of our knowledge, this is the first report detailing the 
successful grafting of M13 onto SPMs for use as a potential affinity matrix in HGMS.  
2. Results 
Genetic and chemical modifications of M13 phage coat proteins 
Figure 1a presents the strategies that were used to genetically modify the pIII coat proteins 
with either a –HHHHHH (M13His) or –CHKKPSKSC [39, 40] (M13Si) peptide to allow the 
phage to be assembled on SPMs that have been coated with either nitrilotriacetic acid (NTA) 
or silica, respectively. These peptides were inserted at the N-terminus of the five pIII proteins 
by synthesizing the appropriate double-stranded DNA sequence and cloning it between the 
EagI and KpnI restriction sites of the pM13KE plasmid (sequences details are presented in the 
Experimental Section). The integrity of the final constructs was confirmed by sequencing the 
phage DNA using the -96gIII primer and propagating the bacteriophage in E. coli ER2738. 
The M13 mutants were grown and purified at a high yield of 20-30 mg per litre of E. coli 
culture, which is similar to the level of expression that was achieved for the wild-type M13 
virus. This result confirmed that the pentavalent display of the foreign binding peptides did 
not negatively influence the ability of the M13 viruses to infect E.coli cells. 
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The pVIII coat protein (Figures 1b and 1c) was chemically modified to allow side-on linkage 
of the phage to the SPMs. Figure 2a shows a MALDI-TOF mass spectra of the M13 phage 
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with a single peak at approximately 5,250 m/z, which was consistent with the mass of the 
amino-acid sequence of the protonated pVIII coat protein of wild-type M13 [41]. Figure 2b 
shows the spectra of a phage that has been reacted with N-hydroxysuccinimido-biotin (NHS-
biotin). At low levels of modification of the M13 phage with NHS-biotin, which we define as 
~400 biotins per phage (as determined by the HABA assay which is described in the 
Supplementary Section), two peaks were observed at 5,246 and 5,470 m/z. The first species 
was wt-pVIII and the second peak was identified as pVIII coat protein modified with a single 
biotin group. Complete reaction of the phage with NHS-LC-biotin resulted in a high-level of 
functionalization of the pVIII protein with ~2,500 biotin molecules per phage. Mass 
spectrometry measurements of phage saturated with a high-level of biotin (Figure 2c) 
indicated that the pVIII proteins were fully modified with either one or two biotin groups. 
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The pVIII protein on M13 was further chemically modified with several other molecules. 
Figure 2d shows the mass spectra of M13 that was reacted with NHS-Cy5 in which can be 
seen the pVIII protein and a single 650 Da Cy5 molecule linked to the pVIII protein. 
Fluorescence measurements of the Cy5 labelled phages indicated that as many as ~600 Cy5 
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molecules reacted with a single phage (please see Supplementary Section). A polyethylene 
glycol polymer of 2,500 Da nominal molecular weight (PEG2500) was also covalently coupled 
to the pVIII protein using the amine reactive NHS chemistry. As shown in Figure 2e, a series 
of peaks were observed in the mass spectra of the pVIII-PEG complex that are characteristic 
of the polydispersity of the PEG polymer. Dual labeling of the M13 has also been 
demonstrated with Cy5 and PEG2500. The first peak (Figure 1f) at approximately 5,900 m/z 
corresponds to the attachment of the Cy5 with a coverage of ~ 200 molecules per phage and a 
second set of peaks at approximatley 7,740 Da were consistent with the PEG2500 moieties. 
Synthesis and characterization of M13-superparamagnetic particles 
Superparamagnetic microparticles were synthesized using emulsion templated Fe3O4 
nanoparticle assembly [8], resulting in particles with an average size of 1 micron, a CV 
of 20 %, and a saturation magnetisation of approximately 55 emu/g (Supplementary Section, 
Figure S2). The M13 phages were non-covalently or covalently linked to these SPMs 
attaching by using either the engineered pIII or pVIII coat proteins. Non-covalent capture 
with the pIII protein was achieved using M13Si or M13His to bind to the silica or NTA 
coated particles, respectively. Controlled phage capture was performed using monoclonal 
anti-pIII antibody coated SPMs. Immobilization through the pVIII protein was achieved using 
either direct covalent coupling to carboxyl-functionalized particles or specific attachment, i.e., 
biotin–phage with neutravidin coated SPMs. 
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Figure 3 presents the fluorescence and colorimetric measurements of the phage bound to the 
SPMs using the five strategies at a fixed reaction concentration of 1010 phage to 5x108 SPMs 
in a single mL reaction volume. Both fluorescence and colorimetric measurements 
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demonstrated similar trends, i.e., EDC/NHS ≈ biotin-neutravidin > Ni-NTA > anti-pVIII > 
silica, although the absolute number of phage per SPM measured by fluorescence was 
consistently higher than the colorimetric results (this systematic difference was attributed to 
the calibration of the colorimetric measurement assay, which underestimated the amount of 
phage on the particles). Direct covalent coupling of the phage to the NHS functionalized 
SPMs using the pVIII surface coat proteins produced the highest coverage of phage. The 
M13-biotin-neutravidin particle assembly strategy also resulted in high immobilization 
efficiency, but the anti-pVIII antibody immobilization approach resulted in a significantly 
lower coverage of M13. For non-covalent immobilization, M13His were detected at 
coverages approximately half of those using the NHS chemistry. The lowest particle coverage 
was obtained using the genetically modified M13Si phage.  
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The physical conformation of the M13 structure on the SPMs was monitored using electron 
microscopy. Figure 4a shows a SEM micrograph of a single particle with a relatively smooth 
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surface. Figure 4b shows M13 covalently immobilized onto a bead through the EDC-NHS 
coupling chemistry in which multiple filamentous structures can be clearly observed tightly 
attached to the surface of the beads. Figures 4c and 4d indicate that the dominant mode of 
assembly of M13His phage to the NTA coated magnetic particles was through the end of the 
phage. This is consistent with a specific interaction in which the five copies of the pIII protein 
bind to functional NTA groups on the SPM surface.  
The phage-particle interaction was studied at higher resolution with TEM. Figure 4e shows a 
micrograph of a single M13His phage projecting normal to the surface of the black SPM at 
the bottom of the image. The orientation of the phage is consistent with a specific attachment 
of the genetically modified pIII protein to this single SPM. Figure 4f shows that the 
attachment of viruses to neutravidin functionalized SPMs through biotinylated functionalized 
pVIII protein resulted in filamentous structures tightly packed to the neutravidin SPM surface.  
In order to test the utility of M13His phage-SPMs as a potential HGMS affinity matrix, we 
carried out affinity separation of the anti-pVIII protein monoclonal antibody as a model 
analyte. These SPMs have a very high magnetic moment, thus separation was very rapid, even 
at low densities of SPMs, typically < 6 mins. The separation was performed in a concentrated 
solution of bovine serium albumin (BSA, 20 mg/mL) and the bound protein was eluted from 
the magnetic matrix using an acidic buffer. Gel electrophoresis followed by MALDI-TOF 
analysis was performed on the purified fraction to estimate the relative purity of the sample. 
BSA was not detected in product effluent from M13His-particles thus we estimated the purity 
to be > 90 %. The presence of antibody in the eluted fraction was confirmed by 
immunoblotting using a specific anti-IgG probe (Figure 3c). We measured the binding 
capacity of the M13His-SPMs to be 10-15 g of antibody removed for one mg of SPM, i.e., 
7.7x107 particles. This is a similar to the binding capacity resulting from protein monolayers 
on the SPMs (e.g. Dynal, Invitrogen). However, in this specific measurement only ten M13 Formatted: Not Highlight
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phage were bound to each SPM and the equilibrium coverage of the phage can theoretically 
reach 10,000 phage per particle. These results indicate that the binding capacity of the 
M13His-SPMs could reach 1000 times higher than that of direct binding chemistries. The 
phage-magnetic particles remained functional in their ability to bind the anti-pVIII antibody 
for up to 5 brief acidification steps given they were stored at low temperature. 
3. Discussion 
In this article we describe the assembly of M13 phage on SPMs using genetic engineering and 
covalent chemical modification to determine the potential of these highly sophisticated 
bionanomaterials for large-scale affinity separation. The side-on assembly of the M13 phage 
on SPMs was achieved by either direct covalent reaction with the SPMs or the specific 
molecular interaction of the pVIII coat protein with a protein on the surface of the SPMs. 
Fluorescence and colorimetric measurements of the binding of the phage to the SPMs, shown 
in Figure 3, demonstrated that both assembly strategies were successful. However, the phage 
coverage was found to be highest for assembly strategies that used strong phage-SPM 
interactions, i.e., EDC-NHS ≈ neutravidin-biotin > anti-pVIII bond. The maximum number of 
phage per SPM, i.e., approximately 13 M13 phages per SPM of the EDC-NHS chemistry, 
resulted in the coupling of 65 % of the phage in the initial reaction to the SPMs. Electron 
microscopy images of the SPMs treated with phage, Figures 4b and 4f, revealed that the 
phage were tightly bound to the bead surface, consistent with the attachment of the phage to 
the beads at multiple points. The SEM images also revealed that EDC-NHS and biotin-
neutravidin chemistries produced a network of phage on the SPMs that, while not fully dense, 
was sufficiently packed such that the majority of the phage crossed over at least one other 
phage at some point. These images suggest that strong phage-SPM interactions are required to 
allow phage to bend around and cross over adjacent phage while still remaining tethered to 
the bead. 
Formatted: Not Highlight
Submitted to  
 
 - 15 - 
The end-on assembly of the filamentous M13 on the SPMs was achieved by genetically 
modifying the five pIII proteins with specific peptide sequences that recognize chemistries on 
the surface of SPMs. Measurements of the amount of phage bound to the SPMs, shown in 
Figure 3, demonstrated that both peptides can be used to immobilize the phage on the surface 
of the particles and that the NTA-His6 bond produced a surface coverage significantly higher 
than M13Si. Electron micrographs, Figures 4c, 4d and 4e, confirm that these phage were 
immobilized in an end-on configuration, providing strong evidence that the assembly is driven 
by the specific molecular interactions of the pIII proteins with the microparticle surface. 
Surprisingly, though, very little M13Si phage was detected on the silica coated particles after 
incubation with PBS-BSA, which suggests that the M13Si-microparticle assembly would not 
be stable in the presence of protein. In contrast, the M13His phage-microparticle binding was 
found to be stable in PBS-BSA. The binding forces of the His6-NTA and peptide-Si bonds to 
their respective targets have been reported to be of the same order of magnitude, i.e., the 
peptide-Si bond has an affinity in the range of 8.7 μM [40] and the His6-NTA bond 
is 10 μM [42]. The introduction of multiple bonds into the assembly produced a geometric 
increase in the overall affinity (avidity) and two His6-NTA bonds have demonstrated a half-
life of hours in serum [42]. This suggests that the stability of the phage-SPM structure resulted 
from factors other than bond energy. Non-specific adsorption of proteins is known to readily 
take place on silica surfaces and lead to the preferential coverage of the strongest binder [43]. 
This suggests the M13Si phage may be displaced from the silica surface due to the 
competitive adsorption of BSA with the glass. Non-specific protein adsorption was expected 
to be less of an issue for the His6-NTA chemistry as the NTA groups were grafted through a 
PEG monolayer that is known to inhibit non-specific adsorption and this was shown to be the 
case. 
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A highly useful feature of the M13 phage for affinity separation is that the filamentous body 
is made of 2,700 pVIII proteins that can be modified to create a high density of functional 
groups [43]. In this study, the reactive residues (e.g. lysine-8) on the pVIII protein were 
targeted for modification with NHS groups, which allowed a highly specific nucleophilic 
reaction to take place in aqueous solution at room temperature. This chemistry was used to 
functionalize the pVIII coat proteins with biotin, Cy5 and much larger macromolecules, i.e., 
2,500 Da molecular weight PEG. Mass spectrometry demonstrated that NHS-biotin can react 
with one or more amine reactive groups accessible to the surface of the phage body, as shown 
in Figures 2b and 2c. Colorimetric measurements indicated that high reaction efficiencies 
could be achieved, i.e., 99 % of the pVIII proteins could be functionalized with biotin groups. 
A significantly lower fraction of the pVIII coat proteins was modified by the larger Cy5 
molecule, i.e., fluorimetry detected that approximately 25 % of the pVIII proteins were bound 
with Cy5, with even lower coverage for the PEG. 
The phage-SPMs seemed to be promising materials for HGMS affinity separation. High-salt 
and acidic buffers as low as pH 2.2 are commonly used to elute target proteins from affinity 
separation supports [39]. The phage-SPMs withstood these same relatively harsh conditions 
without being compromised, which is consistent with the observation that wild-type phage 
retain their infectivity after a brief exposure to these conditions. In this study, anti-pVIII 
antibodies were successfully recovered at high yield on a single step separation. Also, phage-
SPMs could be used up to five times after beeing submitted to the (low pH) elution method 
and NaOH sterilization. We finally demonstrated that the M13 virion could also be modified 
with PEG, a hydrophilic polymer known to inhibit aggregation of colloidal particles and 
protect proteins from enzymatic degradation [44]. These results demonstrate that M13-linked 
magnetic particles can be used to separate specific proteins in a single step and 
simultaneously tolerate the harsh conditions typically inherent in affinity separation. 
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4. Conclusions 
These experiments have demonstrated that phage-SPMs complexes can be created if the M13 
phage is chemically or genetically modified to drive assembly on SPMs in a side or end-on 
configuration. Several observations have been made concerning the successful grafting of 
phage onto SPMs. First, strong specific molecular or covalent interactions must be used to 
drive functional assembly. The use of lower-energy assembly strategies resulted in lower 
phage coverage. Second, the surface chemistry of the beads must be controlled to minimize 
non-specific interactions that block assembly of the phage on the SPM and decrease the purity 
of the final product. While the simplest strategy is chemical modification, either via 
EDC/NHS or biotin produced, this method resulted in some loss of functionality. The most 
convenient method for assembly of phage to the beads is end-on attachment using genetically 
modified pIII proteins using the Ni-NTA binding peptides. Though large-scale HGMF has not 
been demonstrated in this work, the described adsorbent meets many of the criteria identified 
by Franzreb et al. as necessary for use in HGMF applications [10]. In specific, the M13His-
SPM construct promises to be highly useful for large-scale affinity HGMS of high-value 
biomaterials and biopharmaceuticals as 1) it is likely to be highly response to magnetic 
fields, 2) affinity separation can be executed in a single step, 3) the pVIII protein can be easily 
genetically (or chemically) modified, and 4) the pVIII protein is present at very high copy 
numbers. This material also promises to be more cost effective than the conventional 
polymeric or glass affinity separation materials due to the advantageous self-replicating and 
self-assembling properties of the bacteriophage virus. 
 
5. Experimental Section 
 
Design and construction of mutant M13 phage 
Standard phage display molecular biology procedures [39] were used to pentavalently express 
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six histidine residues (M13His) or CHKKPSKSC (Si-M13) peptides fused to the N-terminus 
of the pIII minor coat protein of the wild-type (wtM13) virus [41]. The sequence details and 
restriction sites used for cloning are shown in Figure 1 of the Supplementary Section. Double-
stranded DNA sequences were inserted by Genscript (Piscataway NJ, USA) in the pM13KE 
plasmid (New England Biolabs, Hitchin, Hertfordshire, UK) between the EagI and KpnI sites 
and treatement with T4 ligase yielded pM13KE-His (M13His) and pM13KE-Si (M13Si). The 
ligation products were subcloned into TG1 cells and plated on LB plates in the presence of 
20 μg/mL isopropyl--D-1-thio galactopyranoside (IPTG) and 20 μg/mL 5 bromo-4-chloro-3-
indolyl-β-d-galactopyranosid (X-Gal) to generate blue phage plaques. The integrity of the 
final vector constructions was confirmed by DNA sequencing (Genscript, Piscataway, USA) 
using the ~96gIII primer (New England Biolabs). 
Large-scale amplification of M13 viruses 
The M13 virus was grown and purified using standard microbiology and biochemical 
protocols. An E. coli ER2738 (NEB, Hitchin, Hertfordshire, UK) culture was grown in 1 L of 
Luria Bertani (LB) media (Fisher Scientific, Dublin, Ireland) supplemented with tetracycline 
to mid-log phase and infected with approximately 1012 pfu of M13 bacteriophage. This culture 
was incubated at 37 °C and then shaken at 180 rpm for 5 h. The virus was recovered by: 
centrifuging the culture to remove bacterial cells, precipitating with PEG/NaCl (20 % PEG 
and 2.5 mol/L NaCl), and reconstituting in phosphate buffer saline (Dubelcco-PBS; 0,137 M 
Sodium Chloride, 0.0027 M Potassium Chloride, and 0.0119 M Phosphates), pH 7.4. The 
typical yield was ~20 mg of purified M13 from one litre of infected bacteria. The phage 
solution was further purified by filtration through 0.45 μm pore-size membrane. The 
concentration was evaluated spectrophotometrically as described in the Supplementary 
Section. 
M13 infectivity was determined by plating and plaque counting. Defined dilutions of M13 
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phages were plated on LB agar plates with an ER2738 cell lawn supplemented 
with 20 μg/mL IPTG, 20 μg/mL X-Gal, and 10 μg/mL tetracycline. Plates were examined for 
the presence of blue plaques after 18 h of incubation at 37°C. 
Surface modification of M13 
In a typical chemical modification reaction, a stock solution of M13 phages was diluted 
to ~ 5.109 phage/mL with PBS buffer. Biotinylated phage (M13-biot) was prepared by 
reacting the M13 phage with 5 mg of either NHS-biotin (N-hydroxysuccinimidobiotin) or 
NHS-LC-biotin (succinimidyl-6-(biotinamido)-6-hexanamido hexanoate (Pierce, Thermo 
Scientific, Dublin, Ireland) at 4 ºC. Reactions were stopped by adding Tris to a final 
concentration of 50 mM. Modified phage particles were dialysed (Centricon, Millipore, 
MWCO 10,000 Da) against PBS to remove unreacted reagents. A PEG/NaCl precipitation 
was subsequently performed to purify M13 virus followed by re-suspension in PBS. Biotin 
conjugation to the phage surface was evaluated using the HABA (Sigma-Aldrich Ireland Ltd), 
which has been described in the Supplementary Section. For high surface coverage, viruses 
were diluted to ~ 1.107/mL before modification. For dual modification, M13 was first labelled 
with NHS-Cy5 (Amersham, Buckinghamshire, UK) to generate ~400 dyes/phage particle 
(Supporting Information). The number of Cy5 per phage was determined 
spectrophotometrically at 650 nm using molar extinction coefficient for Cy5 of 250,000. After 
dialysis against PBS, the Cy5-M13 (~5.108/mL) was further modified using PEG-NHS (7 mg 
in carbonate buffer, pH 8.2) (Rapp Polymere GmbH, Tubingen, Germany) for 16 h to 
generate bifunctional M13 particles. 
MALDI-TOF MS of M13 subunit 
M13 was directly spotted onto a MALDI chip at a concentration of 1 mg/mL in MS grade 
alpha cyano-4-hydroxycinnamic acid in 70 % acetonitrile, 30 % water and 0.1 % TFA as the 
matrix. The phage was desalted using a μ-C18® (Millipore, Tullagreen, Ireland) ZipTip. The 
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samples were analyzed using a MALDI-TOF mass spectrometer (LaserToF TT, Scientific 
Analytica Instruments, UK) operating at 20 kV in linear mode. 
SPM synthesis and M13 immobilization on the SPMs 
One micron sized SPM with a 20 % CV was synthesized according to a procedure developed 
by Shang et al [9]. The particles were functionalized with NHS, NTA, silica, neutravidin or 
anti-pIII antibody, using synthetic procedures described in the Supplementary Section. The 
physical properties of the synthesized particles were characterized with a superconducting 
quantum interference device (MPMS, Quantum Design, Magnetic properties measurement 
system), light scatter measurements, and electron microscopy (Supporting Information).  
Immobilization of genetically modified bacteriophages (M13His, M13Si) on the SPMs was 
performed by overnight incubation of 1 mL of 1010 pfu/mL modified M13 viruses 
with 500 µl of ~1.109 beads/mL magnetic beads, with gentle shaking at room temperature on 
an orbital rotator. Wild type, unmodified M13 bacteriophages (wtM13) were used as a control. 
For immobilization of chemically modified phages onto particles, incubation was decreased to 
3 hours in the same conditions. The unbound phages were removed by washing the magnetic 
particles six times with phosphate buffered saline Tween 20 solution (PBST). M13 linked to 
magnetic particles were collected using a permanent magnet, re-suspended in 1 mL of PBST 
buffer, and stored at 4 °C until they were used. Phages were enumerated in the initial solution, 
supernatant/washing solutions, and the number of phage immobilized on magnetic particles 
was estimated by subtraction.  
Phage coverage measured by solid-phase immunoassays and flow cytometry  
Solid-phase colorimetric immunoassays were conducted on the magnetic particles using anti-
M13-HRP (GE Healthcare, Buckinghamshire, UK). The colorimetric response of the assay 
was calibrated against defined concentrations of M13 immobilized on surfaces. The wells of a 
300 µL microtitration plate were coated with increasing concentrations of wt-M13 phages by 
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incubation in PBS buffer overnight at 4°C. Non-immobilized phages were discarded and free 
sites were blocked with 2.5 % (wt) skimmed milk powder in PBS for at least 2 h at room 
temperature. Colorimetric assays were performed by washing the plates with 0.2% Tween 20 
in PBS, incubating with 100 L anti-M13-HRP (1/5000) for 2 h, and reacting with 
the 3,3',5,5'-tetramethylbenzidine solution (One-Step-TMB, Pierce, ThermoFisher, Dublin, 
Ireland). The relative HRP concentrations were determined by stopping the reactions 
with 30 L of a 4M sulphuric acid solution and measuring the absorbance at 450 nm (BIO-
Tek ELISA reader). M13 linked-superparamagnetic particles were detected using the same 
method and then compared to the titration curve obtained from the surfaces.  
Fluorescence assays were conducted on the SPMs using FITC-anti-M13 (Abcam, Cambridge, 
UK). The SPMs were incubated at a concentration of 1.108/mL with know amount of phage in 
solution follow by the addition of 10 μL of FITC-anti-M13 at room temperature for 2 hours. 
After washing three times in PBST, the particles were analyzed on a FACScalibur flow 
cytometer (BD Biosciences, Oxford, UK). Up to 5x104 particles were counted and analyzed 
for fluorescence intensity using dual color lasers at 525 nm and 660-675 nm. 
Separation and Immunoblotting  
Monoclonal anti-pVIII antibody was diluted in a concentrated BSA solution (2.5 %) and the 
mixture was incubated for 16h at 20ºC with 1 mL functionalized magnetic particles 
(10 mg.mL). After extensive washing with PBST until A280 reached 0.001, bound proteins 
were eluted in fractions of 100 μL of pH 2.2 (glycine, 100 mM) and fractions > 0.1 being 
submitted to a MALDI-TOF assay, SDS-PAGE analysis and Western-Blotting. After reaction 
with anti-pVIII epitope antibody, the elution fraction (Glycin 50 mM, pH 2.2) were 
electrophoresed by a 10% SDS-PAGE gel and transferred to a nitrocellulose membrane 
(semi-dry, 20 V, 20 min). The membrane was blocked with 5 % skim milk in PBS at 4 °C 
overnight and incubated with a 1/5000 dilution of anti-mouse IgG labelled to alkaline 
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phosphatase (Abcam) at room temperature for 2 hours. The membrane was washed 6 times 
with PBST (PBS, 0.5 % Tween-20), developed with NBT/BCIP. Recycling was conducted up 
to five times by regenerating the M13-His SPM with NaOH.  After brief exposition of the 
M13-His SPMs to a NaOH solution, the labeled anti-phage antibody was still able to 
recognize the target epitope on the modified phage-SPM.  This is not surprising as the whole 
phage structure is naturally robust toward extreme pH and temperature conditions[21, 22, 29, 31, 37, 
38]. Fe3+ leakage was not experimentally observed. 
Electron microscopy 
A 20 μL solution of magnetic particles functionalized with engineered phage was deposited 
onto a 300-mesh carbon-coated copper grid for 2 min. The grid was stained with a 
fresh 2 % uranyl acetate solution and observations were performed on a TEM (Jeol 2100, Jeol 
Ltd, Japan) operating at 200 keV. Environmental Scanning Electron Microscopy (FEI Quanta 
3D FEG DualBeam, FEI Ltd, USA) imaging was performed at 5 keV by drying the particles 
and gold coating. 
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Figure Captions. 
 
 
Table Of Contents Figure: Rendered images illustrating the M13 bacteriophage assembled 
on superparamagnetic beads through the pIII proteins on the end of the virion or the pVIII 
proteins on the sides of the viron. 
 
 
 
Figure 1 Computer rendered models of the M13 bacteriophage coat proteins reconstructed 
from the crystal structures of the individual proteins. a) Schematic of the M13 phage in which 
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the individual coat proteins have been assembled in a filamentous structure on DNA. A silica 
(M13Si) or hexahistidine (M13His) binding sequence was genetically fused to the N-terminal 
of the pIII coat protein (colored red). b) Top and side-views of the M13 pVIII protein 
assembly along the central axis of the phage with DNA removed. The distance between two 
neighboring pVIII units is approximately 2.7 nm. c) A single subunit structure of coat protein 
pVIII is shown as a ribbon diagram (magenta: DNA-binding segment, grey: hydrophobic 
segment and orange: effective N-terminal domain) with the reactive residues highlighted, of 
which Lys-8 is easily accessible on the phage surface. Chemical modifications can occur on 
the ~2700 copies of pVIII on the whole phage surface (~ 99 % of the phage protein content). 
 
 
Figure 2 Characterization by MALDI-TOF mass spectroscopy of wild and chemically 
modified recombinant M13-His bacteriophages: a) wild-type-pVIII, b) biotinylated–pVIII, c) 
double-biotinylated-pVIII, d) Cy5-pVIII, e) PEG2500-pVIII, and f) Cy5-PEG2500-pVIII. 
 
Figure 3 Characterization of phage binding to SPMs using pIII and pVIII surface coat 
proteins. a) Saturation phage grafting densities on SPMs measured by flow cytometry. 
Immobilized bacteriophages onto magnetic particles were detected using anti-pVIII-FITC 
antibodies. Results are displayed as number of phages per particle. 
b) Measurement of M13 binding to SPMs as a function of phage concentration using a solid-
phase immunoassay. The colorimetric assay was performed with mouse anti-pVIII antibodies. 
Increasing amounts of SPMs functionalized with M13 were incubated with anti-pVIII phage 
antibody coupled to HRP. After washing, peroxidase activity onto magnetic particles was 
measured by TMB detection at 450 nm and compared to the titration curve performed using 
M13 immobilized on a 96-well plate. c) Immunoblot of the affinity purifed fraction. 1: mouse 
IgG control, 2: eluted fraction pH 2.2 (M13His) and 3: final wash fraction (before elution). 
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Figure 4 Electron microscope images of SPMs and phage-SPM complexes. a) SEM image of 
bare SPM. b) SEM image of M13 bacteriophage covalently immobilized through the pVIII 
coat protein on SPMs with the NHS chemistry. c) and d) FE-SEM images illustrating the end-
on assembly of genetically engineered M13His virus on NTA functionalized SPMs. e) TEM 
image acquired using negative staining illustrating the end-on assembly of wild-M13 virus on 
anti-pIII functionalized SPMs. f) TEM images of M13biot bound to neutravidin coated SPM. 
The filamentous structures of M13 are clearly visible on the surface of the SPMs. 
 
 
Proposed Cover Figure. Depiction of the M13 bacteriophage virons immobilized on the 
superparamagnetic beads either through the pIII proteins on the end of the phage or the pVIII 
protein on the side of the phage. These two immobilization schemes result in an end-on 
phage-superparamagnetic bead assembly or a monolayer of phage covering the 
superparamagnetic beads in a side-on orientation, respectively. 
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Supplementary Section 
This supplement contains Materials and Methods, Figures S1 to S3, and References. 
Phage precipitation 
A single phage plaque was added to a 10 mL of 2xYT containing mid-log E.coli ER2738 
and 10 μg/mL of tetracycline. After incubation at 37 ºC for 4 hrs, the culture was centrifuged 
at 6000 g, at 4 ºC for 15 min. Phage was precipitated from supernatant with 1/5 volume of 
PEG buffer (20 % PEG 8000, 2.5 N NaCl). The mixture was kept at 4 ºC overnight and 
centrifuged at 10,000 g for 10 min at 4 ºC. The phage pellet was dissolved in 500 μl of PBS, 
pH 7.4, centrifuged at 20,000 g for 10 min at 4 ºC to remove the remaining cell debris, and 
stored at 4 ºC. The concentration was evaluated spectrophotometrically using an extinction 
coefficient of 3.84 cm2/mg at 269 nm [1, 2]. 
Fluorescent labelling 
M13 (1011 pfu/mL) was added to one vial of the mono-reactive Cy5 dye (GE Healthcare, 
Dublin, Ireland). The reactive NHS-ester covalently attached to aliphatic amino groups on the 
phage surface. After incubation on the orbital shaker at room temperature in the dark for 1 h, 
the unreacting reagents were removed by dialysis and the labelled phages were further 
purified. Fractions were collected as monitored by a UV detector (at 269 nm); the first 
fraction contained labelled phages while subsequent peaks contained unbound fluorophore. 
Labelled phages were stored in the dark at 4°C until use. 
Magnetic particles synthesis and characterization 
Reagents 
Ferrous chloride, ferric chloride, trifluoroacetic acid, TFA, ethanol, perchloric acid, Sodium 
dodecylsulphate, SDS, Hexanes, polyethylenimine 50 wt % (Mw 1300 and Mw 60K, 
potassium carbonate, 2-(N-morpholino)ethanesulfonic acid, 4-morpholineethanesulfonic acid, 
MES, polyacrylicmaleic acid, PAAMA, potassium hydroxide, sulphuric acid, tetraethylortho 
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silicate, TEOS, Nα,Nα-bis(carboxymethyl)-L-lysine hydrate, dextrane, were all purchased 
from Sigma Alrich. Ammonium hydroxide and oleic acid were purchased from Fisher 
Scientific. N-hydroxysulfosuccinimide, sulfo-NHS and, 1-Ethyl-3-
[3 dimethylaminopropyl]carbodiimide hydrochloride, EDC. BOC-NH-PEG-NHS (Mw 3000), 
and CH30-PEG-NHS (Mw 2000) were purchased from RAPP Polymere, Germany. 
Sulfosuccinimidyl 4-[N-maleimidomethyl]cyclohexane-1-carboxylate, Methyl N-succinimidly 
adipate, MSA, was purchased from Thermo Scientific. Neutravidin was purchased from 
Invitrogen. All chemicals and proteins were used as purchased without further purification. 
Buffers used were 50 mM MES buffer pH 6.0, 50 mM carbonate buffer pH 8.2, Phosphate 
buffered saline, PBS (2.7 mM KCl, 0.137 M NaCl and 0.01 M phosphate) pH 9.0. For zeta 
potential measurement, a 1 mM potassium sulphate solution was brought to pH 4, 6, 8 
or 10 using potassium hydroxide or sulphuric acid. 
Hydrophobic ferrofluid synthesis 
A detailed outline of the Iron oxide synthesis can be found elsewhere (Shang, 2006), briefly; 
48 g FeCl2·4H2O and 98 g FeCl3·6H2O were dissolved in 250 mL deoxygenated water in a 
one-litre three neck flask under a N2 atmosphere. The flask was placed into an ice bath whilst 
ammonium hydroxide (200 mL) was added rapidly with vigorous stirring. The solution was 
kept at 0 oC for 45 min, then the solution was heated to 85 oC for one hour, before 30 mL of 
oleic acid was added and heating was continued for a further 60 mins. The flask was allowed 
to cool to room temperature before being transferred to a 600 mL beaker. A magnet was 
placed next to the beaker to collect the black precipitate, which was washed three times with 
ethanol (200 mL). After each wash, a magnet was placed next to the beaker and the ethanol 
solution poured to waste. This process was repeated with DI water (200 mL) three times 
followed by 20 % perchloric acid (200 mL) three times, DI water (200 mL) three times and 
finally ethanol (200 mL) three times. After the last ethanol wash, the solution was discarded 
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and hexane (400 mL) was added to the beaker. The black precipitate (iron oxide 
nanoparticles) was dispersed in hexane resulting in a non-aqueous ferrofluid.  
Micron sized carboxyl superparamagnetic beads synthesis 
The hexane ferrofluid was diluted to a concentration of 15 mg/mL (wt/wt %) of Fe3O4. The 
ferrofluid was mixed with a dextran 25 % solution containing 2 % SDS (wt/wt %) to create a 
crude emulsion, after which it was passed through a shear device at 1 mL/min, with a distance 
between the inner and outer shear wall of 150 mm. The resultant emulsion was collected in a 
bath containing 2 % SDS and the hexane was allowed to evaporate over night creating micron 
sized aggregates of iron oxide nanoparticles. These were then submitted to a carboxyl surface 
chemistry by first incubating them in a 10 wt % PEI (molecular weight 75 K) for 16 hours and 
then incubating them in a 10 wt % PAAMA solution for 5 hours. After each incubation stage, 
the aggregates were washed three times with DI water. 
NHS activated beads  
NHS activation – 1 mL of carboxyl coated beads (5 mg/mL) were placed into a 1.5 mL 
centrifuge tube and washed 3 times with MES buffer before being resuspended in 0.5 mL of 
MES buffer. The beads were then placed into a sonic bath for 2 min, before a solution of 
5 mg EDC, and 5 mg sulfo-NHS, in 0.5 mL MES buffer, was added. The solution was stirred 
rigorously and placed again into the sonicate bath for 30 sec. The beads were incubated at 
room temperature on a rotating wheel for 30 mins, before being washed with MES buffer 
(1 mL) twice. This procedure yielded NHS activated beads. 
Coupling Neutravidin to carboxyl beads 
The same procedure to prepare NHS activated beads was used, after which, the beads were 
incubated with 1 mL neutravidin solution (5 mg/mL) in MES buffer and incubated at room 
temperature for 2 hours on a rotating wheel. To ensure unreacted NHS groups did not remain 
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after 2 hours the protein solution was removed and the beads were incubated in a glycine 
solution pH 8 for 20 mins, then washed with PBS three times and stored at 4 oC until used.  
Silica coating of carboxyl beads 
500 L of beads (10 mg/mL) were added to 5 mL of ethanol, and 10 mL of TEOS in a 15 mL 
falcon tube and stirred at room temperature for 5 mins. Then, 120 mL of ammonium 
hydroxide solution was added with continuous stirring. After 6 hours the beads were collected 
with a magnet and washed 3 times with DI water, before being resuspended in 10 mL of DI 
water and placed in sonic bath for 10 mins and subsequently, washed with water and stored in 
DI at 4oC. This process typically coated the beads with a silica shell of approx 60 nm, 
confirmed by EDAX and TEM imaging (not shown here). 
Surface modification with amine groups 
The same procedure to prepare NHS activated beads was used, after which 1 mL of 5 % PEI 
(MW 1300) solution in carbonate buffer. The particles were sonicated for 5 mins before 
placing them on a rotating wheel at room temperature for 2 hours. They were washed three 
times with carbonate buffer before being resuspended in the buffer of choice (typically 
carbonate buffer) to allow continuation onto the PEG coating stage. 
Surface modification with Polyethyleneglycol (PEG) 
Amine modified beads were prepared fresh for each PEG modification using the procedure 
described above, following the last wash stage in the amine modification step the solution was 
removed. At this stage, 1 mL of PEG solution (5 mg BOC-NH-PEG-NHS and 15 mg mPEG-
NHS in carbonate buffer (as described above) and 0.6 M K2SO4) was added. The beads were 
sonicated for 5 mins before incubating them on rotation wheel for 2 h at 50°C. Finally, the 
particles were washed 3 times with carbonate buffer and sonicated briefly after each wash. 
These particles can be stored in buffer or DI water at 4 °C for up to 2 months. 
Coupling NTA to PEG 
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The BOC group protecting the amine attached to the PEG was removed by washing the beads 
with a 50 % TFA solution for 4 mins. After, the beads were washed with PBS three times and 
resuspended with 1x PBS. 1 mL of MSA solution (2 mg/mL) was added to the particles, after 
incubating the beads with the MSA solution for 2 hours the beads were washed with a PBS 
pH 9.5 solution for 16 hours. This resulted in the amine terminated PEG groups being 
converted to carboxyl groups. At this point the same procedure to activate the beads with 
NHS was used as described above. This yielded a PEG coated particle with carboxyl group 
activated with NHS. The ratio of carboxyl group to methoxy groups was kept constant at 1:3. 
The NHS activated beads were then added to a 1 mL PBS solution containing NTA at 
10 mg/mL for 2 hours before being washed with PBS and subsequently stored in PBS (0.05 % 
tween). 
Zeta potential measurements 
All zeta potential measurements were performed using a Malvern Zetasizer Nano ZS, using 
the DTS-1060 cells. 20 mL of particles were placed into a 1.5 mL centrifuge tube and washed 
three times with 1 mL of the required buffer before being resuspended in appropriate buffer 
and pH. 
 
Reagents, bioinformatics and data analysis 
Streptavidin-horseradish peroxidase polymer conjugate was obtained from Sigma-Aldrich 
Ireland; FITC anti-pVIII antibody from Abcam Laboratories (Cambridge, UK). Anti-pVIII-
HRP monoclonal antibody was purchased from GE Healthcare Ltd. (Buckinghamshire, UK). 
This mouse antibody reacts specifically with the bacteriophage M13 major coat protein 
product of gene VIII. Mouse anti-pIII monoclonal antibody was obtained from NEB (ISIS Ltd, 
Bray, Ireland): it targets C-terminal residues on M13 pIII. All other reagents were purchased 
from Sigma-Aldrich Ireland Ltd (Dublin, Ireland) of molecular biology research grade. Phage 
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solutions and buffers were filtered before use through 0.45 μm and 0.22 μm membranes 
respectively. Neodymium permanent magnet was used according to the manufacturer's 
instructions [3]. Protein Data Bank entries 1IFJ and 1G3P were used as templates for M13 
structure reconstitution. Structural observations of M13 proteins and picture renderings were 
made using PyMol Molecular Graphics System [4]. 
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Supplementary figures 
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Figure S1 Map and sequences of the designed M13 protein pIII mutants (M13His) (a) and 
M13Si) (b). Cloning has been performed into M13KE (NEB) between KpnI and EagI. The 
NcoI restriction site was used for fast screening and capillary electrophoresis DNA 
sequencing (Applied Biosystems) of the final constructs were performed using ~96gIII primer 
(5´-CCC TCA TAG TTA GCG TAA CG- 3).  
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Figure S2: a) Magnetization curve of the particles used in this study. b) Variation of zeta 
potential against pH for the various beads and their surface chemistries. The carboxyl beads 
are predominantly negative across the pH tested. Amine beads appear positive, and the PEG 
coated beads and NTA coated beads are close to zero zeta potential across pH ranges 4-10. c) 
The zeta potential taken at pH 6 for the beads during each preparation stage. They start 
negative with a carboxyl coating, before moving to a positive zeta potential with an amine 
layer. The PEG layer appears to have little effect upon the zeta potential, but converting the 
amine to a NTA group shifts the zeta potential to a negative value. By mixing the beads with 
Ni and then phage the zeta potential shifts to a larger negative value.  
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Figure S3: a) Overlay of fluorescence histograms from M13-linked magnetic particles 
obtained by FACS using anti-pVIII-FITC antibody. 
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